1. Introduction {#sec1-antibiotics-09-00062}
===============

Antimicrobial resistance is a threat to public health. Enterobacterales are some of the most common and pathogenic microorganisms that have acquired resistance to several classes of antimicrobials \[[@B1-antibiotics-09-00062]\]. Particularly concerning is the resistance to carbapenems since these agents are often considered the last resort antibiotics. In addition, infections caused by carbapenem-resistant enterobacteria are associated with higher costs and mortality rates \[[@B2-antibiotics-09-00062],[@B3-antibiotics-09-00062]\].

The most frequently found carbapenem resistance mechanism is the production of carbapenemases, among which *Klebsiella pneumoniae* carbapenemases (KPC) are the most widely distributed worldwide and are endemic in several countries of the Latin American region \[[@B4-antibiotics-09-00062]\]. Ceftazidime/avibactam (CZA) is the combination of a third-generation cephalosporin and a non-β-lactam inhibitor capable of inhibiting several class D, C and A β-lactamases, including the KPC-family enzymes. Several in vitro, in vivo and clinical studies have reported favorable results with CZA against carbapenemase-producing enterobacteria, while being less toxic than other agents commonly used to treat carbapenem-resistant bacteria, such as colistin and aminoglycosides \[[@B5-antibiotics-09-00062],[@B6-antibiotics-09-00062],[@B7-antibiotics-09-00062]\].

Herein, we evaluated the activity of CZA and comparators against 2252 clinical isolates of Enterobacterales from 20 healthcare institutions located in Argentina, Brazil, Chile, Colombia, and Mexico between January 2016 and October 2017.

2. Results {#sec2-antibiotics-09-00062}
==========

The distribution of the 2252 isolates of Enterobacterales per country and species is shown in [Table 1](#antibiotics-09-00062-t001){ref-type="table"}. Overall, 95.8% (2158/2252) of the isolates were susceptible to CZA (minimum inhibitory concentration of 90% of isolates (MIC~90~) ≤1 mg/L). The highest susceptibility was observed in *Escherichia coli* (97.9%), followed by *Serratia marcescens* (94.5%), *Klebsiella aerogenes* (93.3%), *Klebsiella pneumoniae* (92.1%) and isolates of the *Enterobacter cloacae* complex with a susceptibility of 92.0% ([Table 2](#antibiotics-09-00062-t002){ref-type="table"}). Fosfomycin (FOS) and tigecycline (TGC) were the second most active antibiotics with 93.4% of Enterobacterales susceptible, followed by the carbapenems meropenem (MEM) (88.7%), imipenem (IMI) (87.1%) and ertapenem (ETP) (82.4%).

In all five countries, the susceptibility of Enterobacterales to CZA was similarly high, ranging from 99.1% in Chile (MIC~90~ ≤ 1 mg/L), 98.9% in Mexico (MIC~90~ ≤ 1 mg/L), 97.4% in Argentina (MIC~90~ ≤ 1 mg/L), 96.5% in Brazil (minimum inhibitory concentration of 50% of isolates (MIC~50~) ≤ 1 mg/L, MIC~90~ 2 mg/L) to 94.3% in Colombia (MIC~50~ ≤ 1 mg/L, MIC~90~ 2 mg/L). Comparable results were observed for FOS (92.5%--97.4%) and TGC (81.5%--95.8%). For carbapenem non-susceptible (CNS) Enterobacterales, CZA was active against 77.5% of all tested strains (MIC~50~ 2 mg/L, MIC~90~ ≥ 128 mg/L). The activity of CZA was the highest in CNS isolates from Chile (94.8%, MIC~50~ 2 mg/L, MIC~90~ 8 mg/L), followed by Mexico (93.3%, MIC~50~ ≤ 1 mg/L, MIC~90~ 1 mg/L), Brazil (88.6%, MIC~50~ ≤ 1 mg/L, MIC~90~ 32 mg/L), Argentina (80%, MIC~50~ ≤ 1 mg/L, MIC~90~ 64 mg/L), and Colombia (71.3%, MIC~50~ 2 mg/L, MIC~90~ ≥ 128 mg/L) ([Table 1](#antibiotics-09-00062-t001){ref-type="table"}).

For all species of Enterobacterales, regardless of their susceptibility profile, CZA was the compound with the highest activity when compared with other β-lactam agents. For isolates of *E. coli* and *E. cloacae* complex, CZA was superior to all other antimicrobials tested. In the case of *K. pneumoniae* and *K. aerogenes,* the activity of FOS was slightly superior to CZA, whereas for *S. marcescens* both antimicrobials showed a susceptibility of 94.5%.

From the 2252 isolates tested, 396 (17.6%) were found to be CNS; of note, 46.2% were identified as *K. pneumoniae*. CZA was active against 77.5% of the CNS isolates (MIC~50~ 2 mg/L, MIC~90~ ≥ 128 mg/L), with the highest activity against *S. marcescens* (81.5%), while the lowest susceptibility was observed for *K. pneumoniae* (74.3%). For this group, the activity of CZA was superior to all β-lactams and superior or equal to that of FOS for isolates of *E. cloacae* complex, *K. aerogenes* and *S. marcescens*.

3. Discussion {#sec3-antibiotics-09-00062}
=============

This study showed that 95.8% of clinical isolates of Enterobacterales from five Latin American countries, collected between January 2016 and October 2017, were susceptible to CZA (MIC~90~ ≤ 1 mg/L). The susceptibility to CZA between species ranged from 97.9% for *E. coli* to 92.0% for isolates of *E. cloacae* complex. Furthermore, 77.5% of CNS isolates remained susceptible to CZA. These results underline the potential therapeutic role of CZA for patients infected with KPC-producing and other carbapenemase-producing enterobacteria, which are prevalent in the Latin American region \[[@B4-antibiotics-09-00062],[@B7-antibiotics-09-00062]\].

Although the present study might be limited by the small number of isolates from Mexico and Brazil and the fact that they are from a single center in Argentina, Brazil and Mexico, our results are similar to most reports described previously by other authors. In a study by Flamm et al. \[[@B8-antibiotics-09-00062]\], CZA was evaluated against 130 clinical urinary isolates of Enterobacterales collected in 2011 from Argentina, Brazil, Chile, Colombia, Mexico, Panama and Venezuela, finding a MIC~90~ of 0.25 mg/L. Of the evaluated strains, 0.8% were resistant to MEM. Similarly, Karlowsky et al. \[[@B9-antibiotics-09-00062]\] evaluated the activity of CZA and comparators against clinical isolates of Enterobacterales and *P. aeruginosa* collected between 2012 and 2015 from six Latin American countries (Argentina, Brazil, Chile, Colombia, Mexico and Venezuela). In this study, CZA was active against 99.7% of 7665 Enterobacterales, which is similar to our findings. Furthermore, 5.1% of all isolates were carbapenem (MEM) non-susceptible. In the MEM non-susceptible subgroup, the authors observed that CZA was active against 95.4% of isolates, which is significantly higher compared to our observations.

The differences in CZA susceptibility of the non-susceptible subgroups could be explained by the different hospitals and geographical areas included in the study, as well as the changes in the epidemiology of resistance mechanisms between the study periods. For example, in the case of Brazil, susceptibility rates to CZA in this study were inferior to those observed previously against *K. pneumoniae* isolates in a surveillance study by Rossi et al. (100% susceptible) \[[@B10-antibiotics-09-00062]\]. An increase in class B β-lactamases (which were detected in 0.2% of all Enterobacterales by Karlowsky et al.) or the emergence of different mechanisms of resistance to CZA in class A β-lactamase-producing *K. pneumoniae* as reported in the literature could explain this difference \[[@B11-antibiotics-09-00062],[@B12-antibiotics-09-00062]\].

4. Materials and Methods {#sec4-antibiotics-09-00062}
========================

Isolates were collected in each of the participating institutions between January 2016 and October 2017. Upon reception, species confirmation was performed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (Biomeriéux, Marcy-l'Étoile, France). Susceptibility testing was performed in the laboratory of the research group Resistencia Antimicrobiana y Epidemiología Hospitalaria (RAEH), Universidad El Bosque, Bogotá, Colombia. Minimum inhibitory concentrations (MICs) were determined by broth microdilution using customized Sensititre plates (TREK Diagnostic Systems, East Grinstead, West Sussex, UK), with *E. coli* ATCC 25922 as quality control, following Clinical and Laboratory Standards Institute (CLSI) guidelines \[[@B13-antibiotics-09-00062]\]. Antibiotics evaluated included: ceftazidime/avibactam (CZA; 1/4--128/4 mg/L), ceftazidime (CAZ; 2--32 mg/L), cefepime (FEP; 2--64 mg/L), piperacillin/tazobactam (TZP; 2/4--128/4 mg/L), ertapenem (ETP; 0.25--32 mg/L), imipenem (IMP; 0.25--128 mg/L), meropenem (MEM; 0.25--128 mg/L), tigecycline (TGC; 0.25--8 mg/L) and fosfomycin (FOS; 8--128 mg/L). With the exception of FOS and TGC, results were interpreted according to the CLSI 2018 breakpoints \[[@B14-antibiotics-09-00062]\]. FOS breakpoints for Enterobacterales were extrapolated from the *E. coli* breakpoint by CLSI (FOS non-susceptible MIC ≥128 mg/L). United States Food and Drug Administration product package insert criteria were used as breakpoints for TGC (susceptible: ≤2 mg/L; intermediate: 4 mg/L; resistant: ≥8 mg/L) \[[@B15-antibiotics-09-00062]\]. The specific phenotypic subset defined as a carbapenem non-susceptible (CNS) phenotype included isolates displaying a MIC ≥1 mg/L for ETP.

5. Conclusions {#sec5-antibiotics-09-00062}
==============

We report excellent activity of CZA against diverse Enterobacterales collected in Latin America. The lower rates of CZA susceptibility among CNS isolates in our study highlights the importance of active surveillance programs in order to follow the evolution of resistance mechanisms against the antibiotic armamentarium, including newly introduced antimicrobial agents.
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antibiotics-09-00062-t001_Table 1

###### 

Susceptibility of Enterobacterales to ceftazidime/avibactam and comparators by country.

  Microorganism          Number of Isolates   Percentage of Susceptibility                                                    
  ---------------------- -------------------- ------------------------------ ------ ------ ------ ------ ------ ------ ------ ------
  **Argentina**          233                                                                                                  
  *E. coli*              160                  97.5                           53.8   91.3   60     95.6   96.3   96.9   98.1   98.1
  CNS                    7                    57.1                           0      14.3   14.3   \-     14.3   28.6   28.6   57.1
  *K. pneumoniae*        65                   98.5                           52.3   61.5   49.2   81.5   87.7   89.2   93.8   96.9
  CNS                    12                   100                            8.3    8.3    8.3    \-     33.3   41.7   75     91.7
  *E. cloacae* complex   4                    100                            75     75     75     75     75     75     75     75
  CNS                    0                                                                                                    
  *S. marcescens*        4                    75                             75     75     75     75     75     75     75     75
  CNS                    1                    0                              0      0      0      \-     0      0      0      0
  **Brazil**             85                                                                                                   
  *E. coli*              20                   95                             65     65     80     70     75     75     90     100
  CNS                    6                    83.3                           14.3   14.3   42.9   \-     14.3   14.3   57.1   85.7
  *K. pneumoniae*        23                   87                             4.3    8.7    13     21.7   17.4   21.7   73.9   95.7
  CNS                    18                   83.3                           0      0      0      \-     0      0      66.7   94.4
  *E. cloacae* complex   24                   100                            25     29.2   58.3   62.5   83.3   87.5   79.2   79.2
  CNS                    9                    100                            0      11.1   44.4   \-     66.7   55.6   66.7   77.8
  *S. marcescens*        18                   100                            100    61.1   66.7   83.3   88.9   83.3   88.9   83.3
  CNS                    2                    100                            0      0      0      \-     0      0      50     100
  **Chile**              443                                                                                                  
  *E. coli*              347                  99.1                           70.3   76.7   91.1   88.8   94.2   96.5   94.5   94.8
  CNS                    39                   94.9                           23.1   25.6   51.3   \-     53.8   69.2   59     92.3
  *K. pneumoniae*        66                   98.5                           43.9   51.5   60.6   78.8   90.9   83.3   93.9   90.9
  CNS                    14                   92.9                           0      0      14.3   \-     57.1   21.4   92.9   71.4
  *E. cloacae* complex   21                   100                            81     100    90.5   90.5   100    100    95.2   85.7
  CNS                    2                    100                            100    100    50     \-     100    100    100    100
  *S. marcescens*        9                    100                            66.7   66.7   77.8   66.7   100    88.9   100    100
  CNS                    3                    100                            33.3   33.3   33.3   \-     100    66,7   100    100
  **Colombia**           1396                                                                                                 
  *E. coli*              813                  97.3                           79.3   81.8   91.4   90.7   94.7   95.1   96.1   94.1
  CNS                    76                   72.4                           0      0      0      \-     44.7   47.4   64.5   76.3
  *K. pneumoniae*        441                  90.2                           52.4   56.7   61.7   68.9   74.1   76.2   91.2   91.6
  CNS                    137                  68.6                           0      0      0      \-     18.2   23.4   73     80.3
  *E. cloacae* complex   82                   87.8                           47.6   47.6   54.9   58.5   78     78     90.2   80.5
  CNS                    34                   73.5                           11.8   11.8   20.6   \-     29.4   38.2   76.5   70.6
  *S. marcescens*        60                   93.3                           61.7   63.3   63.3   65     66.7   73.3   76.7   93.3
  CNS                    21                   81                             4.8    4.8    19     \-     19     23.8   52.4   81
  **Mexico**             95                                                                                                   
  *E. coli*              69                   100                            34.8   39.1   73.9   87     91.3   97.1   95.7   94.2
  CNS                    9                    100                            11.1   0      11.1   \-     44.4   77.8   66.7   11.1
  *K. pneumoniae*        15                   100                            66.7   66.7   40     86.7   86.7   86.7   100    100
  CNS                    2                    100                            0      0      0      \-     50     50     100    100
  *E. cloacae* complex   11                   90.9                           27.3   18.2   9.1    63.6   18.2   72.7   90.9   100
  CNS                    4                    75                             0      0      0      \-     25     25     100    100

CAZ: ceftazidime; CZA: ceftazidime/avibactam; ETP: ertapenem; FEP: cefepime; FOS: fosfomycin; IMI: imipenem; MEM: meropenem; TGC: tigecycline; TZP: piperacillin/tazobactam

antibiotics-09-00062-t002_Table 2

###### 

Susceptibility of Enterobacterales to ceftazidime/avibactam according to minimum inhibitory concentration (MIC) (mg/L) distribution and susceptibility to comparators.

  Microorganism          Number of Isolates   Ceftazidime/Avibactam   Susceptibility to Comparators (% Isolates Susceptible)                                                                                                                
  ---------------------- -------------------- ----------------------- -------------------------------------------------------- ------ ------ ------ ------ ------ ----- ---- ------ ------ ------ ------ ------ ------ ------ ------ ------ ------
  Enterobacterales       2252                 89                      93.8                                                     95.2   95.8   96.1   96.9   97.7   100   ≤1   2      95.8   64     67.7   79     82.4   87.1   88.7   93.4   93.4
  CNS                    396                  44.7                    66.9                                                     74.7   77.5   78.8   83.1   87.6   100   2    ≥128   77.5   8.6    12.1   26.8   \-     31.6   35.9   68.9   81.3
  *E. coli*              1409                 93.4                    96.9                                                     97.6   97.9   98.2   98.5   99     100   ≤1   ≤1     97.9   71.8   75.7   90.3   90.3   91.8   95.5   95.6   94.8
  CNS                    137                  43.8                    70.1                                                     77.4   80.3   81.8   84.7   89.1   100   2    ≥128   80.3   16.8   21.9   46.7   \-     44.5   53.3   61.3   82.5
  *K. pneumoniae*        610                  81.8                    88.2                                                     91     92.1   92.4   93.9   95.4   100   ≤1   4      92.1   50     53.4   59.2   70     75.6   76.6   91.3   92.5
  CNS                    183                  45.4                    62.9                                                     71.6   74.3   75.4   80.3   85.2   100   2    ≥128   74.3   2.7    4.9    13.7   \-     20.8   22.4   74.3   82
  *E. cloacae* complex   112                  79.5                    88.4                                                     90.2   92     92     96.5   97.4   100   ≤1   4      92     42.9   46.4   51.8   63.4   71.4   79.5   79.5   79.5
  CNS                    41                   46.3                    70.7                                                     75.6   80.5   80.5   90.3   92.7   100   2    32     80.5   7.3    14.6   19.5   \-     39     43.9   80.5   73.2
  *K. aerogenes*         30                   86.7                    90                                                       93.3   93.3   96.6   96.6   100    100   ≤1   2      93.3   66.7   70     83.3   73.3   83.3   83.3   90     96.7
  CNS                    8                    50                      62.5                                                     75     75     87.5   87.5   100    100   ≤1   64     75     12.5   12.5   50     \-     37.5   37.5   50     75
  *S. marcescens*        91                   81.3                    92.3                                                     94.5   94.5   94.5   94.5   95.6   100   ≤1   2      94.5   62.6   64.8   69.2   70.3   73.6   78     80.2   94.5
  CNS                    27                   40.7                    74                                                       81.4   81.4   81.4   81.4   85.1   100   2    ≥128   81.5   7.4    7.4    18.5   \-     25.9   25.9   55.6   81.5

CAZ: ceftazidime; CZA: ceftazidime/avibactam; ETP: ertapenem; FEP: cefepime; FOS: fosfomycin; IMI: imipenem; MEM: meropenem; MIC~50~: minimum inhibitory concentration of 50% of isolates; MIC~90~: minimum inhibitory concentration of 90% of isolates; TGC: tigecycline; TZP: piperacillin/tazobactam; %S: isolates susceptible.
